The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses alterations to the immune ecosystem and bone marrow microenvironment (BME) in patients with immunoglobin light chain (AL) amyloidosis. He emphasizes the significance of targeting the BME in AL amyloidosis for optimal treatment response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, GlaxoSmithKline, AbbVie, Adaptive Biotechnologies, Janssen, Karyopharm, Legend, Novartis, OncoPep, Pfizer, Takeda
Current holder of stock options: Pfizer
